Avinger (NASDAQ:AVGR) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Avinger (NASDAQ:AVGR) in a report issued on Monday. The firm set a “hold” rating on the medical device company’s stock.

Avinger Stock Performance

Avinger stock opened at $0.95 on Monday. Avinger has a 52 week low of $0.90 and a 52 week high of $9.62. The stock has a market capitalization of $1.61 million, a P/E ratio of -0.05 and a beta of 1.17. The stock has a fifty day moving average of $1.24 and a 200-day moving average of $2.26.

Avinger (NASDAQ:AVGR) last issued its earnings results on Thursday, August 8th. The medical device company reported ($2.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($2.39). The business had revenue of $1.85 million for the quarter, compared to analysts’ expectations of $2.55 million. On average, research analysts forecast that Avinger will post -4.69 earnings per share for the current year.

Hedge Funds Weigh In On Avinger

A hedge fund recently bought a new stake in Avinger stock. Armistice Capital LLC acquired a new stake in Avinger, Inc. (NASDAQ:AVGR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned 2.57% of Avinger as of its most recent SEC filing. Institutional investors own 18.30% of the company’s stock.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.